BONESUPPORT: Inconclusive study results, but still a compelling case

Redeye returns with a more in-depth view of the case changes following the inconclusive study results from the FORTIFY trial. We argue that the longer-term prospects of the case remain relatively intact, as we believe BONESUPPORT will recommence its US launch of CERAMENT G for the trauma indication, after anticipated FDA discussions granting a De Novo application. The inconclusive study results are not a “curtains-down” event, which we soon expect the market to realize.

OB

Oscar Bergman

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.